Optimization of Azoles as Anti-Human Immunodeficiency Virus Agents Guided by Free-Energy Calculations
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Efficient optimization of an inactive 2-anilinyl-5-benzyloxadiazole core has been guided by free energy perturbation (FEP) calculations to provide potent non-nucleoside inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (NNRTIs). An FEP "chlorine scan" was performed to identify the most promising sites for substitution of aryl hydrogens. This yielded NNRTIs 8 and 10 with activities (EC50) of 820 and 310 nM for protection of human T-cells from infection by wild-type HIV-1. FEP calculations for additional substituent modifications and change of the core heterocycle readily led to oxazoles 28 and 29, which were confirmed as highly potent anti-HIV agents with activities in the 10-20 nM range. The designed compounds were also monitored for possession of desirable pharmacological properties by use of additional computational tools. Overall, the trends predicted by the FEP calculations were well borne out by the assay results. FEP-guided lead optimization is confirmed as a valuable tool for molecular design including drug discovery; chlorine scans are particularly attractive since they are both straightforward to perform and highly informative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Cited by
Molecular dynamics simulations and drug discovery
Durrant, J. D., & McCammon, J. A. (2011) · BMC Biology · doi:10.1186/1741-7007-9-71 · Cited by 1,403
Biomolecular Simulation: A Computational Microscope for Molecular Biology
Dror, R. O., Dirks, R. M., Grossman, J. P., Xu, H., & Shaw, D. E. (2012) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-042910-155245 · Cited by 1,198
Efficient Drug Lead Discovery and Optimization
Jorgensen, W. L. (2009) · Accounts of Chemical Research · doi:10.1021/ar800236t · Cited by 649
Self-citationComputations of Standard Binding Free Energies with Molecular Dynamics Simulations
Deng, Y., & Roux, B. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp807701h · Cited by 591
Alchemical free energy methods for drug discovery: progress and challenges
Chodera, J. D., Mobley, D. L., Shirts, M. R., Dixon, R. W., Branson, K., & Pande, V. S. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.011 · Cited by 546
Entropy-Enthalpy Compensation: Role and Ramifications in Biomolecular Ligand Recognition and Design
Chodera, J. D., & Mobley, D. L. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130318 · Cited by 531
The future of molecular dynamics simulations in drug discovery
Borhani, D. W., & Shaw, D. E. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9517-y · Cited by 313
“Compound design decisions were based, in part, on calculated estimates of binding free energy differences, determined using free energy perturbation with Monte Carlo sampling, among various Cl-substituted test compounds [37].”
MethodMichel, J., & Essex, J. W. (2010) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-010-9363-3 · Cited by 263
Michel, J., Tirado-Rives, J., & Jorgensen, W. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906058w · Cited by 256
Self-citationHIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
Metadata
- Authors
- Zeevaart, J. G., Wang, L., Thakur, V. V., Leung, C. S., Tirado-Rives, J., Bailey, C. M., Domaoal, R. A., Anderson, K. S., & Jorgensen, W. L.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-06-28
- Volume
- 130
- Issue
- 29
- Pages
- 9492-9499
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2056516302
- Cited by
- 93
- References
- 1
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.